publication date: Sep. 9, 2016

In Brief

Washington University Receives

$10.4 Million NCI SPORE Grant

WASHINGTON UNIVERSITY Siteman Cancer Center received a Specialized Program of Research Excellence five-year grant of $10.4 million to lead a national group of experts in collaborative pancreatic cancer research.

The SPORE focuses on treatment of the deadliest form of pancreatic ductal adenocarcinoma, including development of more effective chemotherapies and a vaccine.

Partner institutions are the University of Rochester, the University of North Carolina at Chapel Hill, and Johns Hopkins University.

The SPORE grant supports four new projects that involve:

• Altering the environment around the tumor to make it more susceptible to immunotherapy, which harnesses a patient’s own immune system to fight cancer. This research is led by David DeNardo, a Washington University assistant professor of medicine, who will work with David Linehan, of the University of Rochester;

• Developing a more effective chemotherapy aimed at targeting pancreatic cancer and inducing tumor cell death. This work is led by William Hawkins, the Neidorff Family and Robert C. Packman Professor of surgery at Washington University and principal investigator of the grant.

• Evaluating for future clinical testing another potential chemotherapy that overcomes tumor resistance. This area of study is led by Andrea Wang-Gillam, a Washington University associate professor of medicine, who will work with Channing Der of the University of North Carolina at Chapel Hill;

·    Conducting preclinical studies of a personalized pancreatic cancer vaccine. This work is led by William Gillanders, a Washington University professor of surgery, who will work with Robert Schreiber, the Alumni Endowed Professor of Pathology and Immunology at Washington University, and Elizabeth Jaffee of Johns Hopkins University.

Three other Washington University faculty members … Continue reading 42-33 Washington University Receives $10.4 Million NCI SPORE Grant

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.